🟠 Conclusions: This once-daily #therapy reduces treatment burden, improving adherence, with the potential to streamline cystic fibrosis management despite study limitations in diversity and placebo comparisons. 
#CRISPR #biotech $VRTX $NTLA $PRME $EDIT @FDA